» Articles » PMID: 26728489

Cancer and Fertility Preservation: International Recommendations from an Expert Meeting

Abstract

In the last years, thanks to the improvement in the prognosis of cancer patients, a growing attention has been given to the fertility issues. International guidelines on fertility preservation in cancer patients recommend that physicians discuss, as early as possible, with all patients of reproductive age their risk of infertility from the disease and/or treatment and their interest in having children after cancer, and help with informed fertility preservation decisions. As recommended by the American Society of Clinical Oncology and the European Society for Medical Oncology, sperm cryopreservation and embryo/oocyte cryopreservation are standard strategies for fertility preservations in male and female patients, respectively; other strategies (e.g. pharmacological protection of the gonads and gonadal tissue cryopreservation) are considered experimental techniques. However, since then, new data have become available, and several issues in this field are still controversial and should be addressed by both patients and their treating physicians.In April 2015, physicians with expertise in the field of fertility preservation in cancer patients from several European countries were invited in Genova (Italy) to participate in a workshop on the topic of "cancer and fertility preservation". A total of ten controversial issues were discussed at the conference. Experts were asked to present an up-to-date review of the literature published on these topics and the presentation of own unpublished data was encouraged. On the basis of the data presented, as well as the expertise of the invited speakers, a total of ten recommendations were discussed and prepared with the aim to help physicians in counseling their young patients interested in fertility preservation.Although there is a great interest in this field, due to the lack of large prospective cohort studies and randomized trials on these topics, the level of evidence is not higher than 3 for most of the recommendations highlighting the need of further research efforts in many areas of this field. The participation to the ongoing registries and prospective studies is crucial to acquire more robust information in order to provide evidence-based recommendations.

Citing Articles

In vitro analysis of the molecular mechanisms of ursolic acid against ovarian cancer.

Zhang R, Zhang Z, Xie L, Yu Z, Gao R, Zhang Z BMC Complement Med Ther. 2025; 25(1):65.

PMID: 39984915 PMC: 11846399. DOI: 10.1186/s12906-025-04808-y.


An efficient interpretable framework for unsupervised low, very low and extreme birth weight detection.

Nawaz A, Ahmad A, Khan S, Masud M, Ghenimi N, Ahmed L PLoS One. 2025; 20(1):e0317843.

PMID: 39883616 PMC: 11781751. DOI: 10.1371/journal.pone.0317843.


Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.

Inojosa H, Schriefer D, Ness N, Dillenseger A, Akgun K, Ziemssen T J Neurol. 2025; 272(2):153.

PMID: 39821478 PMC: 11742466. DOI: 10.1007/s00415-024-12723-4.


Long-Term Effects on Gonadal Function After Treatment of Colorectal Cancer: A Systematic Review and Meta-Analysis.

Anthon C, Vidal A, Recker H, Piccand E, Pape J, Weidlinger S Cancers (Basel). 2024; 16(23).

PMID: 39682193 PMC: 11640400. DOI: 10.3390/cancers16234005.


Contraception Use in Cancer Survivors, Clinical Practice and Patients' Preferences.

Asinaro G, Stigliani S, Chiappe E, Lambertini M, Massarotti C Open Access J Contracept. 2024; 15:135-143.

PMID: 39678079 PMC: 11646390. DOI: 10.2147/OAJC.S431366.


References
1.
Rosendahl M, Greve T, Andersen C . The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2012; 30(1):11-24. PMC: 3553351. DOI: 10.1007/s10815-012-9912-x. View

2.
Quinn G, Vadaparampil S, Gwede C, Miree C, King L, Clayton H . Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv. 2008; 1(2):146-55. DOI: 10.1007/s11764-007-0019-9. View

3.
Brinton L, Scoccia B, Moghissi K, Westhoff C, Niwa S, Ruggieri D . Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2014; 23(4):584-93. PMC: 3979528. DOI: 10.1158/1055-9965.EPI-13-0996. View

4.
Borini A, Levi Setti P, Anserini P, De Luca R, De Santis L, Porcu E . Multicenter observational study on slow-cooling oocyte cryopreservation: clinical outcome. Fertil Steril. 2010; 94(5):1662-8. DOI: 10.1016/j.fertnstert.2009.10.029. View

5.
Levi Setti P, Porcu E, Patrizio P, Vigiliano V, De Luca R, DAloja P . Human oocyte cryopreservation with slow freezing versus vitrification. Results from the National Italian Registry data, 2007-2011. Fertil Steril. 2014; 102(1):90-95.e2. DOI: 10.1016/j.fertnstert.2014.03.052. View